# Ravi Salgia

List of Articles by Year
in descending order

Source: //exaly.com/author-pdf/2223928/publications.pdf

Version: 2025-02-01

| | | | |
|---|---|---|---|
| 417<br>peer-reviewed articles | 25,140<br>peer-reviewed citations | 10277<br>71<br>peer-reviewed h-index | 129755<br>5.87<br>score |
| 477<br>documents | 31692<br>doc citations | 7855<br>81<br>h-index | 66718<br>citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Exploring the potential of TGFβ as a diagnostic marker and therapeutic target against cancer. Biochemical Pharmacology, 2025, 231, 116646. | 3.7 | 27 |
| 2 | Unveiling the potential of gene editing techniques in revolutionizing Cancer treatment: A comprehensive overview. Biochimica Et Biophysica Acta: Reviews on Cancer, 2025, 1880, 189233. | 5.8 | 19 |
| 3 | The Impact of Medicaid Expansion on Stage at Diagnosis of Melanoma Patients: A Retrospective Study. Cancers, 2025, 17, 61. | 2.7 | 2 |
| 4 | DNA walk of specific fused oncogenes exhibit distinct fractal geometric characteristics in nucleotide patterns. Physica A: Statistical Mechanics and Its Applications, 2025, 662, 130437. | 2.1 | 0 |
| 5 | The expanding role of the receptor tyrosine kinase MET as a therapeutic target in non-small cell lung cancer. Cell Reports Medicine, 2025, 6, 101983. | 5.3 | 17 |
| 6 | Strategic advancements in targeting the PI3K/AKT/mTOR pathway for Breast cancer therapy. Biochemical Pharmacology, 2025, 236, 116850. | 3.7 | 63 |
| 7 | Axl Regulation of NK Cell Activity Creates an Immunosuppressive Tumor Immune Microenvironment in Head and Neck Cancer. Cancers, 2025, 17, 994. | 2.7 | 3 |
| 8 | Treatment Approaches for Oligoprogressive Non-Small Cell Lung Cancer: A Review of Ablative Radiotherapy. Cancers, 2025, 17, 1233. | 2.7 | 5 |
| 9 | Conformational dynamics and multimodal interaction of Paxillin with the focal adhesion targeting domain. Science Advances, 2025, 11, . | 8.1 | 10 |
| 10 | Metabolic reprogramming in breast cancer: Pathways driving progression, drug resistance, and emerging therapeutics. Biochimica Et Biophysica Acta: Reviews on Cancer, 2025, 1880, 189396. | 5.8 | 19 |
| 11 | Molecular PET imaging: Unlocking the secrets of cancer metabolism. Biochemical Pharmacology, 2025, 242, 117202. | 3.7 | 15 |
| 12 | Targeting the oncoprotein RLIP as novel therapy for ovarian cancer. Journal of Ovarian Research, 2025, 18, . | 2.8 | 2 |
| 13 | Current paradigm of EGFR in non-small cell lung cancer: A long way forward. Med, 2025, 6, 100803. | 6.2 | 4 |
| 14 | Machine Learning Models for Predicting Gynecological Cancers: Advances, Challenges, and Future Directions. Cancers, 2025, 17, 2799. | 2.7 | 18 |
| 15 | Immune Escape Strategies in Head and Neck Cancer: Evade, Resist, Inhibit, Recruit. Cancers, 2024, 16, 312. | 2.7 | 23 |
| 16 | Comprehending phenotypic plasticity in cancer and evolution. IScience, 2024, 27, 109308. | 2.4 | 5 |
| 17 | Emerging biomarkers and molecular targets for precision medicine in cervical cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2024, 1879, 189106. | 5.8 | 41 |
| 18 | MerTK Drives Proliferation and Metastatic Potential in Triple-Negative Breast Cancer. International Journal of Molecular Sciences, 2024, 25, 5109. | 3.2 | 8 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | A novel HLA-DQB2::MET gene fusion variant in lung adenocarcinoma with prolonged response to tepotinib: a case report. Translational Lung Cancer Research, 2024, 13, 1163-1168. | 1.3 | 5 |
| 20 | Teriflunomide/leflunomide synergize with chemotherapeutics by decreasing mitochondrial fragmentation via DRP1 in SCLC. IScience, 2024, 27, 110132. | 2.4 | 10 |
| 21 | Spatial iTME analysis of KRAS mutant NSCLC and immunotherapy outcome. Npj Precision Oncology, 2024, 8, . | 4.9 | 4 |
| 22 | Enhancing carboplatin sensitivity in ovarian cancer cells by blocking the mercapturic acid pathway transporter. Carcinogenesis, 2024, 45, 696-707. | 2.2 | 2 |
| 23 | RBM10 Mutation as a Potential Negative Prognostic/Predictive Biomarker to Therapy in Non-Small-Cell Lung Cancer. Clinical Lung Cancer, 2024, 25, e411-e419. | 2.1 | 7 |
| 24 | Phenotypic Plasticity and Cancer: A System Biology Perspective. Journal of Clinical Medicine, 2024, 13, 4302. | 1.8 | 4 |
| 25 | Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions. Journal of Clinical Medicine, 2024, 13, 4189. | 1.8 | 63 |
| 26 | Gynecological cancer tumor Microenvironment: Unveiling cellular complexity and therapeutic potential. Biochemical Pharmacology, 2024, 229, 116498. | 3.7 | 26 |
| 27 | Comprehensive investigation of long non-coding RNA HOTAIR polymorphisms and cancer risk: a current meta-analysis encompassing 96,458 participants. Scientific Reports, 2024, 14, . | 2.7 | 6 |
| 28 | From Bench to Bedside: A Team's Approach to Multidisciplinary Strategies to Combat Therapeutic Resistance in Head and Neck Squamous Cell Carcinoma. Journal of Clinical Medicine, 2024, 13, 6036. | 1.8 | 7 |
| 29 | Intrinsic disorder, extraterrestrial peptides, and prebiotic life on the earth. Journal of Biomolecular Structure and Dynamics, 2023, 41, 5481-5485. | 1.8 | 7 |
| 30 | Precision oncology provides opportunities for targeting KRAS-inhibitor resistance. Trends in Cancer, 2023, 9, 42-54. | 8.1 | 51 |
| 31 | Prognostic significance of natural products against multidrug tumor resistance. Cancer Letters, 2023, 557, 216079. | 6.5 | 24 |
| 32 | Integration of artificial intelligence in lung cancer: Rise of the machine. Cell Reports Medicine, 2023, 4, 100933. | 5.3 | 61 |
| 33 | Overcoming Barriers to Tobacco Cessation and Lung Cancer Screening among Racial and Ethnic Minority Groups and Underserved Patients in Academic Centers and Community Network Sites: The City of Hope Experience. Journal of Clinical Medicine, 2023, 12, 1275. | 1.8 | 9 |
| 34 | A Closer Look at EGFR Inhibitor Resistance in Non-Small Cell Lung Cancer through the Lens of Precision Medicine. Journal of Clinical Medicine, 2023, 12, 1936. | 1.8 | 12 |
| 35 | Assessment of Barriers and Challenges to Screening, Diagnosis, and Biomarker Testing in Early-Stage Lung Cancer. Cancers, 2023, 15, 1595. | 2.7 | 26 |
| 36 | Dual Axl/MerTK inhibitor INCB081776 creates a proinflammatory tumor immune microenvironment and enhances anti-PDL1 efficacy in head and neck cancer. Head and Neck, 2023, 45, 1255-1271. | 1.4 | 11 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | LSD1-targeted therapy—a multi-purpose key to unlock immunotherapy in small cell lung cancer. Translational Lung Cancer Research, 2023, 12, 1350-1354. | 1.3 | 9 |
| 38 | Recent Advancement in Breast Cancer Research: Insights from Model Organisms—Mouse Models to Zebrafish. Cancers, 2023, 15, 2961. | 2.7 | 26 |
| 39 | The innate effects of plant secondary metabolites in preclusion of gynecologic cancers: Inflammatory response and therapeutic action. Biochimica Et Biophysica Acta: Reviews on Cancer, 2023, 1878, 188929. | 5.8 | 16 |
| 40 | Radiation Sensitivity: The Rise of Predictive Patient-Derived Cancer Models. Seminars in Radiation Oncology, 2023, 33, 279-286. | 2.4 | 1 |
| 41 | Intrinsically disordered proteins and conformational noise: The hypothesis a decade later. IScience, 2023, 26, 107109. | 2.4 | 10 |
| 42 | Clinical Network Systems Biology: Traversing the Cancer Multiverse. Journal of Clinical Medicine, 2023, 12, 4535. | 1.8 | 13 |
| 43 | Differential Distribution of Brain Metastases from Non-Small Cell Lung Cancer Based on Mutation Status. Brain Sciences, 2023, 13, 1057. | 1.8 | 3 |
| 44 | Selpercatinib and Pralsetinib Induced Chylous Ascites in RET-Rearranged Lung Adenocarcinoma: A Case Series. Clinical Lung Cancer, 2023, 24, 666-671. | 2.1 | 14 |
| 45 | An LC–MS/MS Method for Simultaneous Determination of LB-100 and Its Active Metabolite, Endothall, in Human Plasma. Bioanalysis, 2023, 15, 1095-1107. | 0.8 | 1 |
| 46 | Targeted Therapies in Early-Stage Resectable Non–Small-Cell Lung Cancer: New Kids on the Block. JCO Precision Oncology, 2023, , . | 1.1 | 2 |
| 47 | Phase II Trial of Lung Chemoembolization. Journal of Vascular and Interventional Radiology, 2023, 34, 2090-2092. | 1.0 | 2 |
| 48 | Acquired resistance to KRAS G12C small-molecule inhibitors via genetic/nongenetic mechanisms in lung cancer. Science Advances, 2023, 9, . | 8.1 | 76 |
| 49 | Artificial intelligence and allied subsets in early detection and preclusion of gynecological cancers. Biochimica Et Biophysica Acta: Reviews on Cancer, 2023, 1878, 189026. | 5.8 | 39 |
| 50 | Epigenetic landscape of small cell lung cancer: small image of a giant recalcitrant disease. Seminars in Cancer Biology, 2022, 83, 57-76. | 10.5 | 55 |
| 51 | MicroRNA-1: Diverse role of a small player in multiple cancers. Seminars in Cell and Developmental Biology, 2022, 124, 114-126. | 3.8 | 21 |
| 52 | Near-Complete Response to Combined Pembrolizumab and Platinum-Doublet in a Patient With STK11/KRAS Mutated Advanced Lung Adenocarcinoma. Clinical Lung Cancer, 2022, 23, e137-e139. | 2.1 | 4 |
| 53 | Co-opting disorder into order: Intrinsically disordered proteins and the early evolution of complex multicellularity. International Journal of Biological Macromolecules, 2022, 201, 29-36. | 5.6 | 12 |
| 54 | Novel Therapeutic Targets and Immune Dysfunction in Malignant Pleural Mesothelioma. Frontiers in Pharmacology, 2022, 12, . | 2.6 | 9 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Abstract PO-009: Assessment of geographic and racial/ethnic variables in tobacco use among cancer patients in a widely dispersed academic-led cancer care network. , 2022, , . | | 0 |
| 56 | Abstract PO-011: Use of clinician and nurse tobacco cessation champions to implement a tobacco control program in a geographically disseminated academic center-led clinical network analyzed by patient racial/ethnic group. , 2022, , . | | 1 |
| 57 | Postoperative Radiation Therapy Should Be Used for Completely Resected Stage III-N2 NSCLC in Select Patients. Journal of Thoracic Oncology, 2022, 17, 194-196. | 1.5 | 15 |
| 58 | Intrinsically Disordered Proteins: Critical Components of the Wetware. Chemical Reviews, 2022, 122, 6614-6633. | 42.5 | 90 |
| 59 | Small Cell Lung Cancer Transformation following Treatment in EGFR-Mutated Non-Small Cell Lung Cancer. Journal of Clinical Medicine, 2022, 11, 1429. | 1.8 | 30 |
| 60 | Intrinsically disordered proteins: Ensembles at the limits of Anfinsen's dogma. Biophysics Reviews, 2022, 3, . | 2.3 | 42 |
| 61 | Dynamic Phenotypic Switching and Group Behavior Help Non-Small Cell Lung Cancer Cells Evade Chemotherapy. Biomolecules, 2022, 12, 8. | 3.1 | 25 |
| 62 | Infectious complications of immune checkpoint inhibitors in solid organ malignancies. Cancer Medicine, 2022, 11, 21-27. | 2.0 | 33 |
| 63 | AXL regulates neuregulin1 expression leading to cetuximab resistance in head and neck cancer. BMC Cancer, 2022, 22, . | 2.1 | 17 |
| 64 | Machine learning to refine prognostic and predictive nodal burden thresholds for post-operative radiotherapy in completely resected stage III-N2 non-small cell lung cancer. Radiotherapy and Oncology, 2022, 173, 10-18. | 1.4 | 19 |
| 65 | Leveraging deep learning algorithms for synthetic data generation to design and analyze biological networks. Journal of Biosciences, 2022, 47, . | 1.0 | 32 |
| 66 | Chemokines and NSCLC: Emerging role in prognosis, heterogeneity, and therapeutics. Seminars in Cancer Biology, 2022, 86, 233-246. | 10.5 | 61 |
| 67 | An Updated Review on Radiation Treatment Management in Thymus Cancers. Clinical Lung Cancer, 2022, 23, 561-570. | 2.1 | 6 |
| 68 | Ablative Radiotherapy as a Strategy to Overcome TKI Resistance in EGFR-Mutated NSCLC. Cancers, 2022, 14, 3983. | 2.7 | 8 |
| 69 | Intrinsically disordered BMP4 morphogen and the beak of the finch: Co-option of an ancient axial patterning system. International Journal of Biological Macromolecules, 2022, 219, 366-373. | 5.6 | 9 |
| 70 | RLIP: A necessary transporter protein for translating oxidative stress into pro-obesity and pro-carcinogenic signaling. Biochimica Et Biophysica Acta: Reviews on Cancer, 2022, 1877, 188803. | 5.8 | 6 |
| 71 | Utilization of model-agnostic explainable artificial intelligence frameworks in oncology: a narrative review. Translational Cancer Research, 2022, 11, 3853-3868. | 1.0 | 81 |
| 72 | Clinical and Molecular Features of KRAS-Mutated Lung Cancer Patients Treated with Immune Checkpoint Inhibitors. Cancers, 2022, 14, 4933. | 2.7 | 25 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Pyramidal Decision Support Framework Leverages Subspecialty Expertise across Enterprise to Achieve Superior Cancer Outcomes and Personalized, Precision Care Plans. Journal of Clinical Medicine, 2022, 11, 6738. | 1.8 | 10 |
| 74 | Targeting RLIP with CRISPR/Cas9 controls tumor growth. Carcinogenesis, 2021, 42, 48-57. | 2.2 | 21 |
| 75 | Evaluation of Omics-Based Strategies for the Management of Advanced Lung Cancer. JCO Oncology Practice, 2021, 17, e257-e265. | 2.3 | 10 |
| 76 | Progressive Neurologic Changes in a Patient With Metastatic Non–Small-Cell Lung Cancer: Cancer Effects or a Secondary Diagnosis?. JCO Oncology Practice, 2021, 17, 52-53. | 2.3 | 0 |
| 77 | Multicohort Retrospective Validation of a Predictive Biomarker for Topoisomerase I Inhibitors. Clinical Colorectal Cancer, 2021, 20, e129-e138. | 1.1 | 3 |
| 78 | JNJ-64041757 (JNJ-757), a Live, Attenuated, Double-Deleted Listeria monocytogenes–Based Immunotherapy in Patients With NSCLC: Results From Two Phase 1 Studies. JTO Clinical and Research Reports, 2021, 2, 100103. | 0.6 | 12 |
| 79 | The Effects of Time to Treatment Initiation for Patients With Non–small-cell Lung Cancer in the United States. Clinical Lung Cancer, 2021, 22, e84-e97. | 2.1 | 57 |
| 80 | The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC). Cell Reports Medicine, 2021, 2, 100186. | 5.3 | 141 |
| 81 | Integrating Academic and Community Cancer Care and Research through Multidisciplinary Oncology Pathways for Value-Based Care: A Review and the City of Hope Experience. Journal of Clinical Medicine, 2021, 10, 188. | 1.8 | 29 |
| 82 | Prevention of mammary carcinogenesis in MMTV-neu mice by targeting RLIP. Molecular Carcinogenesis, 2021, 60, 213-223. | 2.1 | 4 |
| 83 | Co-stimulatory and co-inhibitory Immune Markers in Solid Tumors With MET Alterations. Future Science OA, 2021, 7, . | 1.4 | 2 |
| 84 | RLIP depletion induces apoptosis associated with inhibition of JAK2/STAT3 signaling in melanoma cells. Carcinogenesis, 2021, 42, 742-752. | 2.2 | 5 |
| 85 | Predicting Survival Duration With MRI Radiomics of Brain Metastases From Non-small Cell Lung Cancer. Frontiers in Oncology, 2021, 11, . | 1.7 | 37 |
| 86 | RNA-based therapies: A cog in the wheel of lung cancer defense. Molecular Cancer, 2021, 20, . | 19.9 | 92 |
| 87 | Disparate outcomes in nonsmall cell lung cancer by immigration status. Cancer Medicine, 2021, 10, 2660-2667. | 2.0 | 4 |
| 88 | Germline mutations and age at onset of lung adenocarcinoma. Cancer, 2021, 127, 2801-2806. | 2.7 | 24 |
| 89 | Group Behavior and Emergence of Cancer Drug Resistance. Trends in Cancer, 2021, 7, 323-334. | 8.1 | 43 |
| 90 | Activating p53 function by targeting RLIP. Biochimica Et Biophysica Acta: Reviews on Cancer, 2021, 1875, 188512. | 5.8 | 5 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Evolution of core archetypal phenotypes in progressive high grade serous ovarian cancer. Nature Communications, 2021, 12, . | 10.8 | 56 |
| 92 | Molecular and Clinical Features of Hospital Admissions in Patients with Thoracic Malignancies on Immune Checkpoint Inhibitors. Cancers, 2021, 13, 2653. | 2.7 | 3 |
| 93 | ST6GalNAc-I promotes lung cancer metastasis by altering MUC5AC sialylation. Molecular Oncology, 2021, 15, 1866-1881. | 2.8 | 41 |
| 94 | The Small Molecule BC-2059 Inhibits Wingless/Integrated (Wnt)-Dependent Gene Transcription in Cancer through Disruption of the Transducin β-Like 1-β-Catenin Protein Complex. Journal of Pharmacology and Experimental Therapeutics, 2021, 378, 77-86. | 2.3 | 18 |
| 95 | Twitter as a Tool to Spread Communication Regarding Genitourinary Cancers During the COVID-19 Pandemic. Kidney Cancer, 2021, 5, 73-78. | 0.5 | 1 |
| 96 | Evaluation of Somatic Mutations in Solid Metastatic Pan-Cancer Patients. Cancers, 2021, 13, 2776. | 2.7 | 10 |
| 97 | Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy. Journal of Thoracic Oncology, 2021, 16, 1030-1041. | 1.5 | 120 |
| 98 | The Association between Polluted Neighborhoods andTP53-Mutated Non–Small Cell Lung Cancer. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 1498-1505. | 0.6 | 24 |
| 99 | Essential role of the histone lysine demethylase KDM4A in the biology of malignant pleural mesothelioma (MPM). British Journal of Cancer, 2021, 125, 582-592. | 4.1 | 12 |
| 100 | Immunotherapy in Non-Small Cell Lung Cancer Patients with Brain Metastases: Clinical Challenges and Future Directions. Cancers, 2021, 13, 3407. | 2.7 | 15 |
| 101 | Protein Phosphatase 2A as a Therapeutic Target in Small Cell Lung Cancer. Molecular Cancer Therapeutics, 2021, 20, 1820-1835. | 1.2 | 13 |
| 102 | Elevated Eosinophil Count Following Pembrolizumab Treatment for Non-Small Cell Lung Cancer. Cureus, 2021, , . | 0.3 | 5 |
| 103 | Immune Checkpoint Inhibitor–Induced Myocarditis with Myositis/Myasthenia Gravis Overlap Syndrome: A Systematic Review of Cases. Oncologist, 2021, 26, 1052-1061. | 2.5 | 201 |
| 104 | Targeting CA-125 Transcription by Development of a Conditionally Replicative Adenovirus for Ovarian Cancer Treatment. Cancers, 2021, 13, 4265. | 2.7 | 9 |
| 105 | Improving Care for Patients With Stage III or IV NSCLC: Learnings for Multidisciplinary Teams From the ACCC National Quality Survey. JCO Oncology Practice, 2021, 17, e1120-e1130. | 2.3 | 11 |
| 106 | Usefulness of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients With Non-small Cell Lung Cancer. Chest, 2021, 160, 1095-1107. | 0.8 | 36 |
| 107 | Therapeutic Potential of Olaparib in Combination With Pembrolizumab in a Young Patient With a Maternally Inherited BRCA2 Germline Variant: A Research Report. Clinical Lung Cancer, 2021, 22, e703-e707. | 2.1 | 7 |
| 108 | Improved Survival Outcomes in Medically Fit Patients With Early-Stage Non–Small-Cell Lung Cancer Undergoing Stereotactic Body Radiotherapy. Clinical Lung Cancer, 2021, 22, e678-e683. | 2.1 | 3 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Targeting the mercapturic acid pathway for the treatment of melanoma. Cancer Letters, 2021, 518, 10-22. | 6.5 | 8 |
| 110 | Inhibitors of the Transcription Factor STAT3 Decrease Growth and Induce Immune Response Genes in Models of Malignant Pleural Mesothelioma (MPM). Cancers, 2021, 13, 7. | 2.7 | 17 |
| 111 | Protein conformational dynamics and phenotypic switching. Biophysical Reviews, 2021, 13, 1127-1138. | 2.3 | 17 |
| 112 | The Mitochondrion as an Emerging Therapeutic Target in Cancer. Trends in Molecular Medicine, 2020, 26, 119-134. | 6.4 | 184 |
| 113 | SOX9: The master regulator of cell fate in breast cancer. Biochemical Pharmacology, 2020, 174, 113789. | 3.7 | 68 |
| 114 | Presence and structure-activity relationship of intrinsically disordered regions across mucins. FASEB Journal, 2020, 34, 1939-1957. | 2.3 | 12 |
| 115 | RLIP controls receptor-ligand signaling by regulating clathrin-dependent endocytosis. Biochimica Et Biophysica Acta: Reviews on Cancer, 2020, 1873, 188337. | 5.8 | 8 |
| 116 | Activation of EPHA2-ROBO1 Heterodimer by SLIT2 Attenuates Non-canonical Signaling and Proliferation in Squamous Cell Carcinomas. IScience, 2020, 23, 101692. | 2.4 | 11 |
| 117 | Hyperprogression on immunotherapy with complete response to chemotherapy in a NSCLC patient with high PD-L1 and STK11. Medicine (United States), 2020, 99, e22323. | 1.0 | 18 |
| 118 | A Non-genetic Mechanism Involving the Integrin β4/Paxillin Axis Contributes to Chemoresistance in Lung Cancer. IScience, 2020, 23, 101496. | 2.4 | 36 |
| 119 | Small Cell Lung Cancer from Traditional to Innovative Therapeutics: Building a Comprehensive Network to Optimize Clinical and Translational Research. Journal of Clinical Medicine, 2020, 9, 2433. | 1.8 | 10 |
| 120 | Lysocardiolipin acyltransferase regulates NSCLC cell proliferation and migration by modulating mitochondrial dynamics. Journal of Biological Chemistry, 2020, 295, 13393-13406. | 1.3 | 18 |
| 121 | Salmonella-Based Therapy Targeting Indoleamine 2,3-Dioxygenase Restructures the Immune Contexture to Improve Checkpoint Blockade Efficacy. Biomedicines, 2020, 8, 617. | 2.5 | 22 |
| 122 | Acquired Resistance to PD-1/PD-L1 Blockade in Lung Cancer: Mechanisms and Patterns of Failure. Cancers, 2020, 12, 3851. | 2.7 | 44 |
| 123 | Rapid progression of disease from immunotherapy following targeted therapy: insights into treatment management and sequence. Journal of Thoracic Disease, 2020, 12, 5096-5103. | 0.9 | 0 |
| 124 | Role of immunotherapy and co-mutations on KRAS-mutant non- small cell lung cancer survival. Journal of Thoracic Disease, 2020, 12, 5086-5095. | 0.9 | 44 |
| 125 | Therapeutic targeting of miRNA-216b in cancer. Cancer Letters, 2020, 484, 16-28. | 6.5 | 18 |
| 126 | Differentiating Peripherally-Located Small Cell Lung Cancer From Non-small Cell Lung Cancer Using a CT Radiomic Approach. Frontiers in Oncology, 2020, 10, . | 1.7 | 51 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | Non-Small Cell Lung Cancer from Genomics to Therapeutics: A Framework for Community Practice Integration to Arrive at Personalized Therapy Strategies. Journal of Clinical Medicine, 2020, 9, 1870. | 1.8 | 23 |
| 128 | Association of molecular characteristics with survival in advanced non-small cell lung cancer patients treated with checkpoint inhibitors. Lung Cancer, 2020, 146, 174-181. | 1.8 | 11 |
| 129 | Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune Evasion. Cancer Cell, 2020, 38, 79-96.e11. | 28.4 | 712 |
| 130 | Radiomic prediction of mutation status based on MR imaging of lung cancer brain metastases. Magnetic Resonance Imaging, 2020, 69, 49-56. | 1.2 | 55 |
| 131 | Implementing Lung Cancer Screening and Prevention in Academic Centers, Affiliated Network Offices and Collaborating Care Sites. Journal of Clinical Medicine, 2020, 9, 1820. | 1.8 | 11 |
| 132 | Complex Oncological Decision-Making Utilizing Fast-and-Frugal Trees in a Community Setting—Role of Academic and Hybrid Modeling. Journal of Clinical Medicine, 2020, 9, 1884. | 1.8 | 6 |
| 133 | Association of TGF-β1 Polymorphisms with Breast Cancer Risk: A Meta-Analysis of Case–Control Studies. Cancers, 2020, 12, 471. | 2.7 | 9 |
| 134 | Dose-Escalation Trial of the ALK, MET & ROS1 Inhibitor, Crizotinib, in Patients with Advanced Cancer. Future Oncology, 2020, 16, 4289-4301. | 1.7 | 14 |
| 135 | Precision medicine and actionable alterations in lung cancer: A single institution experience. PLoS ONE, 2020, 15, e0228188. | 1.5 | 9 |
| 136 | The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping. Cancer Treatment Reviews, 2020, 87, 102022. | 6.0 | 71 |
| 137 | Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti–c-Met Antibody, in Patients with Advanced Solid Tumors. Molecular Cancer Therapeutics, 2020, 19, 1210-1217. | 1.2 | 27 |
| 138 | USP22 Interacts with PALB2 and Promotes Chemotherapy Resistance via Homologous Recombination of DNA Double-Strand Breaks. Molecular Cancer Research, 2020, 18, 424-435. | 2.0 | 25 |
| 139 | Prolonged survival and response to tepotinib in a non-small-cell lung cancer patient with brain metastases harboring MET exon 14 mutation: a research report. Journal of Physical Education and Sports Management, 2020, 6, a005785. | 0.8 | 10 |
| 140 | AXL Mediates Cetuximab and Radiation Resistance Through Tyrosine 821 and the c-ABL Kinase Pathway in Head and Neck Cancer. Clinical Cancer Research, 2020, 26, 4349-4359. | 4.5 | 40 |
| 141 | Effects of selected deubiquitinating enzyme inhibitors on the proliferation and motility of lung cancer and mesothelioma cell lines. International Journal of Oncology, 2020, , . | 3.6 | 1 |
| 142 | Small Cell Lung Cancer Therapeutic Responses Through Fractal Measurements: From Radiology to Mitochondrial Biology. Journal of Clinical Medicine, 2019, 8, 1038. | 1.8 | 11 |
| 143 | Notch signaling in breast cancer: From pathway analysis to therapy. Cancer Letters, 2019, 461, 123-131. | 6.5 | 118 |
| 144 | Prolonged Pharmacokinetic Interaction Between Capecitabine and a CYP2C9 Substrate, Celecoxib. Journal of Clinical Pharmacology, 2019, 59, 1632-1640. | 1.3 | 12 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | The gut microbiome and response to immune checkpoint inhibitors: preclinical and clinical strategies. Clinical and Translational Medicine, 2019, 8, . | 4.1 | 107 |
| 146 | Monitoring and Determining Mitochondrial Network Parameters in Live Lung Cancer Cells. Journal of Clinical Medicine, 2019, 8, 1723. | 1.8 | 6 |
| 147 | Phenotypic Switching of Naïve T Cells to Immune-Suppressive Treg-Like Cells by Mutant KRAS. Journal of Clinical Medicine, 2019, 8, 1726. | 1.8 | 35 |
| 148 | EPHA2 mutations with oncogenic characteristics in squamous cell lung cancer and malignant pleural mesothelioma. Oncogenesis, 2019, 8, . | 3.3 | 27 |
| 149 | RLIP inhibition suppresses breast-to-lung metastasis. Cancer Letters, 2019, 447, 24-32. | 6.5 | 16 |
| 150 | Optimal adjuvant therapy in clinically N2 non-small cell lung cancer patients undergoing neoadjuvant chemotherapy and surgery: The importance of pathological response and lymph node ratio. Lung Cancer, 2019, 133, 136-143. | 1.8 | 25 |
| 151 | Synergistic efficacy of RLIP inhibition and 2'-hydroxyflavanone against DMBA-induced mammary carcinogenesis in SENCAR mice. Molecular Carcinogenesis, 2019, 58, 1438-1449. | 2.1 | 13 |
| 152 | Structural and Dynamical Order of a Disordered Protein: Molecular Insights into Conformational Switching of PAGE4 at the Systems Level. Biomolecules, 2019, 9, 77. | 3.1 | 24 |
| 153 | Combined Checkpoint Inhibition and Chemotherapy: New Era of 1st-Line Treatment for Non-Small-Cell Lung Cancer. Molecular Therapy - Oncolytics, 2019, 13, 1-6. | 3.2 | 35 |
| 154 | Early mortality of stage IV non-small cell lung cancer in the United States. Acta Oncológica, 2019, 58, 1095-1101. | 1.7 | 11 |
| 155 | RLIP: An existential requirement for breast carcinogenesis. Biochimica Et Biophysica Acta: Reviews on Cancer, 2019, 1871, 281-288. | 5.8 | 10 |
| 156 | Anaplastic Lymphoma Kinase (ALK)-positive Tumors. American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, 42, 337-344. | 1.1 | 10 |
| 157 | Ubiquitin-specific protease 22 is critical to in vivo angiogenesis, growth and metastasis of non-small cell lung cancer. Cell Communication and Signaling, 2019, 17, . | 6.2 | 54 |
| 158 | Opportunities for improving cancer treatment using systems biology. Current Opinion in Systems Biology, 2019, 17, 41-50. | 1.2 | 6 |
| 159 | The DNA walk and its demonstration of deterministic chaos—relevance to genomic alterations in lung cancer. Bioinformatics, 2019, 35, 2738-2748. | 3.2 | 13 |
| 160 | 2'-Hydroxyflavanone induced changes in the proteomic profile of breast cancer cells. Journal of Proteomics, 2019, 192, 233-245. | 1.9 | 12 |
| 161 | The Brigatinib Experience: A New Generation of Therapy for ALK-Positive Non-Small-Cell Lung Cancer. Future Oncology, 2018, 14, 1897-1908. | 1.7 | 6 |
| 162 | EphB4: A promising target for upper aerodigestive malignancies. Biochimica Et Biophysica Acta: Reviews on Cancer, 2018, 1869, 128-137. | 5.8 | 21 |

| # | Article | IF | Citations |
|---|---|---|---|
| 163 | Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma. Cancer Biology and Therapy, 2018, 19, 316-327. | 3.2 | 102 |
| 164 | Untying the gordion knot of targeting MET in cancer. Cancer Treatment Reviews, 2018, 66, 95-103. | 6.0 | 22 |
| 165 | B-Cell-Specific Diversion of Glucose Carbon Utilization Reveals a Unique Vulnerability in B Cell Malignancies. Cell, 2018, 173, 470-484.e18. | 23.4 | 127 |
| 166 | Phase 1 Study of Accelerated Hypofractionated Radiation Therapy With Concurrent Chemotherapy for Stage III Non-Small Cell Lung Cancer: CALGB 31102 (Alliance). International Journal of Radiation Oncology Biology Physics, 2018, 101, 177-185. | 1.3 | 47 |
| 167 | Capecitabine and Celecoxib as a Promising Therapy for Thymic Neoplasms. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 963-966. | 1.1 | 5 |
| 168 | Complete Pathologic Response When Adding Pembrolizumab to Neoadjuvant Chemotherapy in Stage IIIA Non–Small-Cell Lung Cancer. Journal of Oncology Practice, 2018, 14, 569-571. | 2.9 | 6 |
| 169 | Managing Patients With Relapsed Small-Cell Lung Cancer. Journal of Oncology Practice, 2018, 14, 359-366. | 2.9 | 55 |
| 170 | Combination systemic therapies with immune checkpoint inhibitors in pancreatic cancer: overcoming resistance to single-agent checkpoint blockade. Clinical and Translational Medicine, 2018, 7, . | 4.1 | 39 |
| 171 | 1556. Infectious Disease Complications with Use of Checkpoint Inhibitors in Solid Organ Malignancies. Open Forum Infectious Diseases, 2018, 5, S484-S484. | 0.7 | 2 |
| 172 | Prostate-Associated Gene 4 (PAGE4): Leveraging the Conformational Dynamics of a Dancing Protein Cloud as a Therapeutic Target. Journal of Clinical Medicine, 2018, 7, 156. | 1.8 | 13 |
| 173 | Inhibiting crosstalk between MET signaling and mitochondrial dynamics and morphology: a novel therapeutic approach for lung cancer and mesothelioma. Cancer Biology and Therapy, 2018, 19, 1023-1032. | 3.2 | 18 |
| 174 | Metastasis of breast tumor cells to brain is suppressed by targeting RLIP alone and in combination with 2'-Hydroxyflavanone. Cancer Letters, 2018, 438, 144-153. | 6.5 | 13 |
| 175 | Stereotactic body radiation therapy (SBRT) for early-stage lung cancer in the elderly. Seminars in Oncology, 2018, 45, 210-219. | 2.8 | 71 |
| 176 | A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2018, 82, 309-317. | 1.3 | 15 |
| 177 | Effective osimertinib treatment in a patient with discordant T790 M mutation detection between liquid biopsy and tissue biopsy. BMC Cancer, 2018, 18, . | 2.1 | 6 |
| 178 | Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. , 2018, 6, . | | 1,178 |
| 179 | 2'-Hydroxyflavanone inhibits in vitro and in vivo growth of breast cancer cells by targeting RLIP76. Molecular Carcinogenesis, 2018, 57, 1751-1762. | 2.1 | 25 |
| 180 | Differential Response of MET inhibition by Glesatinib (MGCD265) and Sitravatinib (MGCD516) in Non-small Cell Lung Cancer and Malignant Mesothelioma. FASEB Journal, 2018, 32, . | 2.3 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 181 | A randomized phase II study of LY2510924 and carboplatin/etoposide versus carboplatin/etoposide in extensive-disease small cell lung cancer. Lung Cancer, 2017, 105, 7-13. | 1.8 | 68 |
| 182 | Loss of H2B monoubiquitination is associated with poor-differentiation and enhanced malignancy of lung adenocarcinoma. International Journal of Cancer, 2017, 141, 766-777. | 2.8 | 38 |
| 183 | Canonical and alternative transcript expression of PAX6 and CXCR4 in pancreatic cancer. Oncology Letters, 2017, 13, 4027-4034. | 1.1 | 5 |
| 184 | The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy. Cancer Treatment Reviews, 2017, 55, 181-189. | 6.0 | 16 |
| 185 | TOPK (T-LAK cell-originated protein kinase) inhibitor exhibits growth suppressive effect on small cell lung cancer. Cancer Science, 2017, 108, 488-496. | 2.9 | 33 |
| 186 | MET in Lung Cancer: Biomarker Selection Based on Scientific Rationale. Molecular Cancer Therapeutics, 2017, 16, 555-565. | 1.2 | 157 |
| 187 | Prognostic and predictive value of circulating tumor cells and CXCR4 expression as biomarkers for a CXCR4 peptide antagonist in combination with carboplatin-etoposide in small cell lung cancer: exploratory analysis of a phase II study. Investigational New Drugs, 2017, 35, 334-344. | 1.6 | 39 |
| 188 | Differential responsiveness of MET inhibition in non-small-cell lung cancer with altered CBL. Scientific Reports, 2017, 7, . | 2.7 | 20 |
| 189 | Empowering survivors after colorectal and lung cancer treatment: Pilot study of a Self-Management Survivorship Care Planning intervention. European Journal of Oncology Nursing, 2017, 29, 125-134. | 2.1 | 43 |
| 190 | Synergistic Anti-Cancer Effect of Baicalein and Metformin against Human Lung Cancer. Journal of the American College of Surgeons, 2017, 225, S35-S36. | 0.8 | 0 |
| 191 | Value-Based Medicine and Integration of Tumor Biology. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, , 833-840. | 4.5 | 7 |
| 192 | Value-Based Medicine and Integration of Tumor Biology. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 833-840. | 4.5 | 2 |
| 193 | Tumor Heterogeneity and Therapeutic Resistance. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, , e585-e593. | 4.5 | 62 |
| 194 | Post-crizotinib management of effective ceritinib therapy in a patient with ALK-positive non-small cell lung cancer. BMC Cancer, 2016, 16, . | 2.1 | 1 |
| 195 | Prognostic and Predictive Value inKRASin Non–Small-Cell Lung Cancer. JAMA Oncology, 2016, 2, 805. | 10.9 | 159 |
| 196 | Mutation testing for directing upfront targeted therapy and post-progression combination therapy strategies in lung adenocarcinoma. Expert Review of Molecular Diagnostics, 2016, 16, 737-749. | 2.3 | 25 |
| 197 | Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment. Cancer Letters, 2016, 380, 494-504. | 6.5 | 169 |
| 198 | Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab. Molecular Cancer Therapeutics, 2016, 15, 2175-2186. | 1.2 | 39 |

| # | Article | IF | Citations |
|---|---|---|---|
| 199 | Unique fractal evaluation and therapeutic implications of mitochondrial morphology in malignant mesothelioma. Scientific Reports, 2016, 6, . | 2.7 | 38 |
| 200 | Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial. Lancet Oncology, The, 2016, 17, 1683-1696. | 16.1 | 337 |
| 201 | PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma. Scientific Reports, 2016, 6, . | 2.7 | 25 |
| 202 | Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization. Oncologist, 2016, 21, 762-770. | 2.5 | 125 |
| 203 | Systemic Therapies in the Treatment of Non-Small-Cell Lung Cancer Brain Metastases. Future Oncology, 2016, 12, 1045-1058. | 1.7 | 11 |
| 204 | Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?. Journal of Thoracic Oncology, 2016, 11, 453-474. | 1.5 | 178 |
| 205 | C. elegansand mutants with chronic nicotine exposure as a novel model of cancer phenotype. Cancer Biology and Therapy, 2016, 17, 91-103. | 3.2 | 5 |
| 206 | Tumor Heterogeneity and Therapeutic Resistance. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 36, e585-e593. | 4.5 | 14 |
| 207 | Concurrent EGFR Mutation and ALK Translocation in Non-Small Cell Lung Cancer. Cureus, 2016, , . | 0.3 | 26 |
| 208 | Role Played by Paxillin and Paxillin Tyrosine Phosphorylation in Hepatocyte Growth Factor/Sphingosine-1-Phosphate-Mediated Reactive Oxygen Species Generation, Lamellipodia Formation, and Endothelial Barrier Function. Pulmonary Circulation, 2015, 5, 619-630. | 1.3 | 24 |
| 209 | Novel EPHB4 Receptor Tyrosine Kinase Mutations and Kinomic Pathway Analysis in Lung Cancer. Scientific Reports, 2015, 5, . | 2.7 | 23 |
| 210 | Multiple Endocrine Disruption by the MET/ALK Inhibitor Crizotinib in Patients With Non–small Cell Lung Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2015, 38, 442-447. | 1.1 | 10 |
| 211 | HABP2 is a Novel Regulator of Hyaluronan-Mediated Human Lung Cancer Progression. Frontiers in Oncology, 2015, 5, . | 1.7 | 37 |
| 212 | Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors. Cancer Discovery, 2015, 5, 850-859. | 6.8 | 756 |
| 213 | A new PET/CT volumetric prognostic index for non-small cell lung cancer. Lung Cancer, 2015, 89, 43-49. | 1.8 | 23 |
| 214 | Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non–Small Cell Lung Cancer Who Previously Progressed on Erlotinib. Clinical Cancer Research, 2015, 21, 4321-4326. | 4.5 | 81 |
| 215 | Lung cancer—a fractal viewpoint. Nature Reviews Clinical Oncology, 2015, 12, 664-675. | 54.3 | 191 |
| 216 | Engineering Synthetic Antibody Inhibitors Specific for LD2 or LD4 Motifs of Paxillin. Journal of Molecular Biology, 2015, 427, 2532-2547. | 2.9 | 10 |

| # | Article | IF | Citations |
|---|---|---|---|
| 217 | Leptomeningeal carcinomatosis in esophageal cancer: a case series and systematic review of the literature. Ecological Management and Restoration, 2015, 28, 772-781. | 0.6 | 27 |
| 218 | AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research, 2015, 21, 2601-2612. | 4.5 | 113 |
| 219 | A Multicenter Phase I Study of Pazopanib in Combination with Paclitaxel in First-Line Treatment of Patients with Advanced Solid Tumors. Molecular Cancer Therapeutics, 2015, 14, 461-469. | 1.2 | 31 |
| 220 | Diagnostic Challenges in Non-Small-Cell Lung Cancer: An Integrated Medicine Approach. Future Oncology, 2015, 11, 489-500. | 1.7 | 22 |
| 221 | PAX3 and FOXD3 Promote CXCR4 Expression in Melanoma. Journal of Biological Chemistry, 2015, 290, 21901-21914. | 1.3 | 24 |
| 222 | ROS1 rearranged non-small cell lung cancer brain metastases respond to low dose radiotherapy. Journal of Clinical Neuroscience, 2015, 22, 1978-1979. | 1.0 | 7 |
| 223 | Whole-animal mounts of Caenorhabditis elegans for 3D imaging using atomic force microscopy. Nanomedicine: Nanotechnology, Biology, and Medicine, 2015, 11, 1971-1974. | 2.3 | 11 |
| 224 | Integrative Analysis of Head and Neck Cancer Identifies Two Biologically Distinct HPV and Three Non-HPV Subtypes. Clinical Cancer Research, 2015, 21, 870-881. | 4.5 | 352 |
| 225 | Activating the Expression of Human K-rasG12D Stimulates Oncogenic Transformation in Transgenic Goat Fetal Fibroblast Cells. PLoS ONE, 2014, 9, e90059. | 1.5 | 5 |
| 226 | The Mu Opioid Receptor Promotes Opioid and Growth Factor-Induced Proliferation, Migration and Epithelial Mesenchymal Transition (EMT) in Human Lung Cancer. PLoS ONE, 2014, 9, e91577. | 1.5 | 197 |
| 227 | Brain metastases in non-small-cell lung cancer: better outcomes through current therapies and utilization of molecularly targeted approaches. CNS Oncology, 2014, 3, 61-75. | 1.3 | 15 |
| 228 | Phase I Dose-Escalation Study of Onartuzumab as a Single Agent and in Combination with Bevacizumab in Patients with Advanced Solid Malignancies. Clinical Cancer Research, 2014, 20, 1666-1675. | 4.5 | 66 |
| 229 | Expression of the EPHB4 receptor tyrosine kinase in head and neck and renal malignancies – implications for solid tumors and potential for therapeutic inhibition. Growth Factors, 2014, 32, 202-206. | 1.2 | 13 |
| 230 | Fibroblast growth factor signaling and inhibition in non-small cell lung cancer and their role in squamous cell tumors. Cancer Medicine, 2014, 3, 681-692. | 2.0 | 27 |
| 231 | Role of PAX8 in the regulation of MET and RON receptor tyrosine kinases in non-small cell lung cancer. BMC Cancer, 2014, 14, . | 2.1 | 16 |
| 232 | Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy. Molecular Cancer, 2014, 13, . | 19.9 | 57 |
| 233 | Analysis of 1,115 Patients Tested for MET Amplification and Therapy Response in the MD Anderson Phase I Clinic. Clinical Cancer Research, 2014, 20, 6336-6345. | 4.5 | 78 |
| 234 | Geographic Variation in Radiologist Capacity and Widespread Implementation of Lung Cancer CT Screening. Journal of Medical Screening, 2014, 21, 207-215. | 1.2 | 25 |

| # | Article | IF | Citations |
|---|---|---|---|
| 235 | Combined MET Inhibition and Topoisomerase I Inhibition Block Cell Growth of Small Cell Lung Cancer. Molecular Cancer Therapeutics, 2014, 13, 576-584. | 1.2 | 19 |
| 236 | Non-small cell lung cancer is susceptible to induction of DNA damage responses and inhibition of angiogenesis by telomere overhang oligonucleotides. Cancer Letters, 2014, 343, 14-23. | 6.5 | 23 |
| 237 | Role of c-Met/Phosphatidylinositol 3-Kinase (PI3k)/Akt Signaling in Hepatocyte Growth Factor (HGF)-mediated Lamellipodia Formation, Reactive Oxygen Species (ROS) Generation, and Motility of Lung Endothelial Cells. Journal of Biological Chemistry, 2014, 289, 13476-13491. | 1.3 | 87 |
| 238 | Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer. New England Journal of Medicine, 2014, 371, 1963-1971. | 26.4 | 1,892 |
| 239 | Transactivation of the Receptor-tyrosine Kinase Ephrin Receptor A2 Is Required for the Low Molecular Weight Hyaluronan-mediated Angiogenesis That Is implicated in Tumor Progression. Journal of Biological Chemistry, 2014, 289, 24043-24058. | 1.3 | 38 |
| 240 | Nuclear Epidermal Growth Factor Receptor Is a Functional Molecular Target in Triple-Negative Breast Cancer. Molecular Cancer Therapeutics, 2014, 13, 1356-1368. | 1.2 | 59 |
| 241 | AXL Mediates Resistance to Cetuximab Therapy. Cancer Research, 2014, 74, 5152-5164. | 2.6 | 187 |
| 242 | Mitochondrial dynamics: biology and therapy in lung cancer. Expert Opinion on Investigational Drugs, 2014, 23, 675-692. | 2.4 | 49 |
| 243 | Dramatic Antitumor Effects of the Dual MET/RON Small-Molecule Inhibitor LY2801653 in Non–Small Cell Lung Cancer. Cancer Research, 2014, 74, 884-895. | 2.6 | 60 |
| 244 | MET and PI3K/mTOR as a Potential Combinatorial Therapeutic Target in Malignant Pleural Mesothelioma. PLoS ONE, 2014, 9, e105919. | 1.5 | 53 |
| 245 | EphB4 as a therapeutic target in mesothelioma. BMC Cancer, 2013, 13, . | 2.1 | 33 |
| 246 | MET As a Possible Target for Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2013, 31, 1089-1096. | 12.4 | 193 |
| 247 | Initial Clinical Sensitivity and Acquired Resistance to MET Inhibition in MET-Mutated Papillary Renal Cell Carcinoma. Journal of Clinical Oncology, 2013, 31, e254-e258. | 12.4 | 29 |
| 248 | Lipopolysaccharide-induced phosphorylation of c-Met tyrosine residue 1003 regulates c-Met intracellular trafficking and lung epithelial barrier function. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2013, 305, L56-L63. | 2.2 | 17 |
| 249 | Critical Role for the Receptor Tyrosine Kinase EPHB4 in Esophageal Cancers. Cancer Research, 2013, 73, 184-194. | 2.6 | 51 |
| 250 | Teaching Video Neuro Images : Myokymia and nerve hyperexcitability as components of Morvan syndrome due to malignant thymoma. Neurology, 2013, 80, . | 0.7 | 5 |
| 251 | Critical Role of S1PR1 and Integrin β4 in HGF/c-Met-mediated Increases in Vascular Integrity. Journal of Biological Chemistry, 2013, 288, 2191-2200. | 1.3 | 47 |
| 252 | A Multicenter Phase II Study of Ganetespib Monotherapy in Patients with Genotypically Defined Advanced Non–Small Cell Lung Cancer. Clinical Cancer Research, 2013, 19, 3068-3077. | 4.5 | 219 |

| # | Article | IF | Citations |
|---|---|---|---|
| 253 | Paxillin mutations affect focal adhesions and lead to altered mitochondrial dynamics. Cancer Biology and Therapy, 2013, 14, 679-691. | 3.2 | 43 |
| 254 | The EphB4 Receptor Tyrosine Kinase Promotes Lung Cancer Growth: A Potential Novel Therapeutic Target. PLoS ONE, 2013, 8, e67668. | 1.5 | 70 |
| 255 | Etoposide and Temozolomide in Combination for the Treatment of Progressive Small-Cell Lung Cancer Central Nervous System Metastases: Two Cases. Tumori, 2013, 99, e73-e76. | 1.1 | 2 |
| 256 | Lack of Association of C-Met-N375S Sequence Variant with Lung Cancer Susceptibility and Prognosis. International Journal of Medical Sciences, 2013, 10, 988-994. | 1.9 | 24 |
| 257 | Characterization of NOL7 Gene Point Mutations, Promoter Methylation, and Protein Expression in Cervical Cancer. International Journal of Gynecological Pathology, 2012, 31, 15-24. | 1.1 | 13 |
| 258 | Targeting myeloid-derived suppressor cells augments antitumor activity against lung cancer. ImmunoTargets and Therapy, 2012, , 7. | 3.2 | 26 |
| 259 | Hypofractionated Image-Guided Radiation Therapy for Patients with Limited Volume Metastatic Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2012, 7, 376-381. | 1.5 | 97 |
| 260 | Phase II Study of the Multitargeted Tyrosine Kinase Inhibitor XL647 in Patients with Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2012, 7, 856-865. | 1.5 | 44 |
| 261 | Three-Dimensional Stereoscopic Volume Rendering of Malignant Pleural Mesothelioma. International Surgery, 2012, 97, 65-70. | 0.1 | 2 |
| 262 | Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncology, The, 2012, 13, 1011-1019. | 16.1 | 1,234 |
| 263 | Quality of Life After Radical Pleurectomy Decortication for Malignant Pleural Mesothelioma. Annals of Thoracic Surgery, 2012, 94, 1086-1092. | 2.6 | 43 |
| 264 | Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin's lymphoma, and neuroblastoma. Targeted Oncology, 2012, 7, 199-210. | 2.5 | 30 |
| 265 | A Novel Classification of Lung Cancer into Molecular Subtypes. PLoS ONE, 2012, 7, e31906. | 1.5 | 104 |
| 266 | Differential expression of RON in small and non–small cell lung cancers. Genes Chromosomes and Cancer, 2012, 51, 841-851. | 1.7 | 33 |
| 267 | Inhibition of mitochondrial fission prevents cell cycle progression in lung cancer. FASEB Journal, 2012, 26, 2175-2186. | 2.3 | 557 |
| 268 | Targeted and Cytotoxic Therapy in Coordinated Sequence (TACTICS): Erlotinib, Bevacizumab, and Standard Chemotherapy for Non–Small-Cell Lung Cancer, A Phase II Trial. Clinical Lung Cancer, 2012, 13, 123-128. | 2.1 | 10 |
| 269 | Development of The American Association for Thoracic Surgery guidelines for low-dose computed tomography scans to screen for lung cancer in North America. Journal of Thoracic and Cardiovascular Surgery, 2012, 144, 25-32. | 2.2 | 114 |
| 270 | The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups. Journal of Thoracic and Cardiovascular Surgery, 2012, 144, 33-38. | 2.2 | 597 |

| # | Article | IF | Citations |
|---|---|---|---|
| 271 | Proteomic characterization of non-small cell lung cancer in a comprehensive translational thoracic oncology database. Journal of Clinical Bioinformatics, 2011, 1, 8. | 3.4 | 10 |
| 272 | Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncology, The, 2011, 12, 1004-1012. | 16.1 | 874 |
| 273 | Role of MetMAb (OA-5D5) in c-MET active lung malignancies. Expert Opinion on Biological Therapy, 2011, 11, 1655-1662. | 1.9 | 49 |
| 274 | MET and Phosphorylated MET as Potential Biomarkers in Lung Cancer. Journal of Environmental Pathology, Toxicology and Oncology, 2011, 30, 341-354. | 1.2 | 28 |
| 275 | The Novel Role of the Mu Opioid Receptor in Lung Cancer Progression. Anesthesia and Analgesia, 2011, 112, 558-567. | 1.5 | 255 |
| 276 | Phase 2 Trial of Linifanib (ABT-869) in Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2011, 6, 1418-1425. | 1.5 | 68 |
| 277 | Bortezomib for Patients with Advanced-Stage Bronchioloalveolar Carcinoma: A California Cancer Consortium Phase II Study (NCI 7003). Journal of Thoracic Oncology, 2011, 6, 1741-1745. | 1.5 | 10 |
| 278 | Generation of Comprehensive Thoracic Oncology Database - Tool for Translational Research. Journal of Visualized Experiments, 2011, , . | 0.2 | 4 |
| 279 | Personalized Treatment of Lung Cancer. Seminars in Oncology, 2011, 38, 274-283. | 2.8 | 39 |
| 280 | Mind-mapping for lung cancer: Towards a personalized therapeutics approach. Advances in Therapy, 2011, 28, 173-194. | 2.7 | 29 |
| 281 | Prognostic significance of angiogenesis and angiogenic growth factors in nonsmall cell lung cancer. Cancer, 2011, 117, 3889-3899. | 2.7 | 51 |
| 282 | An E3 ubiquitin ligase: c-Cbl. Cancer, 2011, 117, 5344-5350. | 2.7 | 30 |
| 283 | RON(MST1R)is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma. Cancer Biology and Therapy, 2011, 12, 9-46. | 3.2 | 82 |
| 284 | Fyn Is Downstream of the HGF/MET Signaling Axis and Affects Cellular Shape and Tropism in PC3 Cells. Clinical Cancer Research, 2011, 17, 3112-3122. | 4.5 | 34 |
| 285 | Novel Functional Germline Variants in the VEGF Receptor 2 Gene and Their Effect on Gene Expression and Microvessel Density in Lung Cancer. Clinical Cancer Research, 2011, 17, 5257-5267. | 4.5 | 77 |
| 286 | Paxillin expression and amplification in early lung lesions of high-risk patients, lung adenocarcinoma and metastatic disease. Journal of Clinical Pathology, 2011, 64, 16-24. | 1.3 | 45 |
| 287 | Takotsubo Cardiomyopathy in a Patient With Squamous Cell Esophageal Carcinoma. Journal of Clinical Oncology, 2011, 29, e598-e600. | 12.4 | 8 |
| 288 | Multicenter Phase II Trial of Motexafin Gadolinium and Pemetrexed for Second-Line Treatment in Patients with Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2011, 6, 786-789. | 1.5 | 17 |

| # | Article | IF | Citations |
|---|---|---|---|
| 289 | Durable Complete Response of Metastatic Gastric Cancer with Anti-Met Therapy Followed by Resistance at Recurrence. Cancer Discovery, 2011, 1, 573-579. | 6.8 | 111 |
| 290 | The role of the c-Met pathway in lung cancer and the potential for targeted therapy. Therapeutic Advances in Medical Oncology, 2011, 3, 171-184. | 2.1 | 115 |
| 291 | Crizotinib: ALK/Met inhibitor, oncolytic. Drugs of the Future, 2011, 36, 91. | 0.2 | 15 |
| 292 | Crizotinib: ALK/Met inhibitor, oncolytic. Drugs of the Future, 2011, 36, 0091. | 0.2 | 3 |
| 293 | Rapid and Dramatic Radiographic and Clinical Response to an ALK Inhibitor (Crizotinib, PF02341066) in an ALK Translocation-Positive Patient with Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2010, 5, 2044-2046. | 1.5 | 73 |
| 294 | CBL Is Frequently Altered in Lung Cancers: Its Relationship to Mutations in MET and EGFR Tyrosine Kinases. PLoS ONE, 2010, 5, e8972. | 1.5 | 101 |
| 295 | EphA2 Mutation in Lung Squamous Cell Carcinoma Promotes Increased Cell Survival, Cell Invasion, Focal Adhesions, and Mammalian Target of Rapamycin Activation. Journal of Biological Chemistry, 2010, 285, 18575-18585. | 1.3 | 108 |
| 296 | Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer. New England Journal of Medicine, 2010, 363, 1693-1703. | 26.4 | 4,327 |
| 297 | Novel Oncogenic Mutations of CBL in Human Acute Myeloid Leukemia That Activate Growth and Survival Pathways Depend on Increased Metabolism. Journal of Biological Chemistry, 2010, 285, 32596-32605. | 1.3 | 52 |
| 298 | MET molecular mechanisms and therapies in lung cancer. Cell Adhesion and Migration, 2010, 4, 146-152. | 2.3 | 64 |
| 299 | The role of chemokine receptor CXCR4 in lung cancer. Cancer Biology and Therapy, 2010, 9, 409-416. | 3.2 | 64 |
| 300 | NADPH oxidases regulate cell growth and migration in myeloid cells transformed by oncogenic tyrosine kinases. Leukemia, 2010, 25, 281-289. | 3.7 | 101 |
| 301 | Expression Patterns of PAX5, c-Met, and Paxillin in Neuroendocrine Tumors of the Lung. Archives of Pathology and Laboratory Medicine, 2010, 134, 1702-1705. | 1.7 | 44 |
| 302 | The Role of EGFR Inhibition in the Treatment of Non-Small Cell Lung Cancer. Oncologist, 2009, 14, 1116-1130. | 2.5 | 61 |
| 303 | PAX6 Is Expressed in Pancreatic Cancer and Actively Participates in Cancer Progression through Activation of the MET Tyrosine Kinase Receptor Gene. Journal of Biological Chemistry, 2009, 284, 27524-27532. | 1.3 | 55 |
| 304 | Ethnic Differences and Functional Analysis of MET Mutations in Lung Cancer. Clinical Cancer Research, 2009, 15, 5714-5723. | 4.5 | 186 |
| 305 | Role of c-Met in Cancer: Emphasis on Lung Cancer. Seminars in Oncology, 2009, 36, S52-S58. | 2.8 | 55 |
| 306 | PAX5 is expressed in small-cell lung cancer and positively regulates c-Met transcription. Laboratory Investigation, 2009, 89, 301-314. | 1.8 | 108 |

| # | Article | IF | Citations |
|---|---|---|---|
| 307 | FYN is overexpressed in human prostate cancer. BJU International, 2009, 103, 171-177. | 2.1 | 83 |
| 308 | The MET axis as a therapeutic target. Update on Cancer Therapeutics, 2009, 3, 109-118. | 0.7 | 33 |
| 309 | MET as a target for treatment of chest tumors. Lung Cancer, 2009, 63, 169-179. | 1.8 | 117 |
| 310 | MET Pathway as a Therapeutic Target. Journal of Thoracic Oncology, 2009, 4, 444-447. | 1.5 | 70 |
| 311 | MET, HGF, EGFR, and PXN Gene Copy Number in Lung Cancer Using DNA Extracts from FFPE Archival Samples and Prognostic Significance. Journal of Environmental Pathology, Toxicology and Oncology, 2009, 28, 89-98. | 1.2 | 37 |
| 312 | NADPH Oxidases Are Important Regulators of Growth and Migration in Myeloid Neoplasms.. Blood, 2009, 114, 2190-2190. | 3.6 | 0 |
| 313 | Expression and mutational analysis of MET in human solid cancers. Genes Chromosomes and Cancer, 2008, 47, 1025-1037. | 1.7 | 301 |
| 314 | Effect of a c-Met-specific, ATP-competitive small-molecule inhibitor SU11274 on human ovarian carcinoma cell growth, motility, and invasion. International Journal of Gynecological Cancer, 2008, 18, 976-984. | 2.2 | 38 |
| 315 | Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: A trial of the Chicago, PMH, and California Phase II consortia. Gynecologic Oncology, 2008, 110, 49-55. | 2.3 | 155 |
| 316 | Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancer. Journal of Carcinogenesis, 2008, 7, 9. | 3.4 | 196 |
| 317 | C. elegans as a model organism for in vivo screening in cancer: effects of human c-Met in lung cancer affect C. elegans vulva phenotypes. Cancer Biology and Therapy, 2008, 7, 856-863. | 3.2 | 31 |
| 318 | Randomized Phase II Study of Carboplatin and Etoposide With or Without thebcl-2Antisense Oligonucleotide Oblimersen for Extensive-Stage Small-Cell Lung Cancer: CALGB 30103. Journal of Clinical Oncology, 2008, 26, 870-876. | 12.4 | 166 |
| 319 | Biomarkers in Lung Cancer: From Early Detection to Novel Therapeutics and Decision Making. Biomarkers in Medicine, 2008, 2, 577-586. | 1.0 | 56 |
| 320 | Phase I Trial of Erlotinib-Based Multimodality Therapy for Inoperable Stage III Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2008, 3, 1003-1011. | 1.5 | 66 |
| 321 | EGFR-Targeted Therapeutics: Focus on SCCHN and NSCLC. Scientific World Journal, The, 2008, 8, 909-919. | 1.7 | 25 |
| 322 | Novel Transforming Mutations of CBL in Human Acute Myeloid Leukemia. Blood, 2008, 112, 2948-2948. | 3.6 | 2 |
| 323 | Lymphatic Vessel Density Is Not Associated With Lymph Node Metastasis in Non–Small Cell Lung Carcinoma. Archives of Pathology and Laboratory Medicine, 2008, 132, 1882-1888. | 1.7 | 20 |
| 324 | Activation of HGF/c-Met pathway contributes to the reactive oxygen species generation and motility of small cell lung cancer cells. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2007, 292, L1488-L1494. | 2.2 | 54 |

| # | Article | IF | Citations |
|---|---|---|---|
| 325 | Lung carcinoma in African Americans. Nature Clinical Practice Oncology, 2007, 4, 118-129. | 6.6 | 47 |
| 326 | CD44 Regulates Hepatocyte Growth Factor-mediated Vascular Integrity. Journal of Biological Chemistry, 2007, 282, 30643-30657. | 1.3 | 117 |
| 327 | Chemotherapy and High Dose Radiotherapy Followed by Resection for Locally Advanced Nonsmall Cell Lung Cancers. American Journal of Clinical Oncology: Cancer Clinical Trials, 2007, 30, 258-263. | 1.1 | 9 |
| 328 | Biomarker discovery in lung cancer—promises and challenges of clinical proteomics. Mass Spectrometry Reviews, 2007, 26, 451-466. | 5.0 | 60 |
| 329 | Downstream signalling and specific inhibition of c-MET/HGF pathway in small cell lung cancer: implications for tumour invasion. British Journal of Cancer, 2007, 97, 368-377. | 4.1 | 168 |
| 330 | Key Signaling Pathways and Targets in Lung Cancer Therapy. Clinical Lung Cancer, 2007, 8, S52-S60. | 2.1 | 12 |
| 331 | Lysophosphatidic acid modulates c-Met redistribution and hepatocyte growth factor/c-Met signaling in human bronchial epithelial cells through PKC δ and E-cadherin. Cellular Signalling, 2007, 19, 2329-2338. | 2.7 | 31 |
| 332 | c-Met and hepatocyte growth factor: Potential as novel targets in cancer therapy. Current Oncology Reports, 2007, 9, 102-108. | 2.8 | 126 |
| 333 | Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma. Cancer Chemotherapy and Pharmacology, 2007, 61, 549-558. | 1.3 | 62 |
| 334 | Diffuse alveolar damage after a single dose of topotecan in a patient with pulmonary fibrosis and small cell lung cancer. Lung Cancer, 2006, 54, 243-245. | 1.8 | 16 |
| 335 | Epidermal growth factor receptor mutations and susceptibility to targeted therapy in lung cancer. Respirology, 2006, 11, 687-692. | 2.7 | 32 |
| 336 | A review of topoisomerase inhibition in lung cancer. Cancer Biology and Therapy, 2006, 5, 1600-1607. | 3.2 | 36 |
| 337 | Therapeutic targeting of receptor tyrosine kinases in lung cancer. Expert Opinion on Therapeutic Targets, 2005, 9, 533-559. | 2.8 | 22 |
| 338 | Molecular Biology of Malignant Mesothelioma: A Review. Hematology/Oncology Clinics of North America, 2005, 19, 997-1023. | 1.5 | 16 |
| 339 | Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species. Blood, 2005, 105, 1717-1723. | 3.6 | 221 |
| 340 | c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Letters, 2005, 225, 1-26. | 6.5 | 507 |
| 341 | Novel Therapies in Lung Cancer. Hematology/Oncology Clinics of North America, 2005, 19, 343-367. | 1.5 | 4 |
| 342 | Receptor Tyrosine Kinases and Inhibitors in Lung Cancer. Scientific World Journal, The, 2004, 4, 589-604. | 1.7 | 45 |

| # | Article | IF | Citations |
|---|---|---|---|
| 343 | Modulation of c-Kit/SCF Pathway Leads to Alterations in Topoisomerase-I Activity in Small Cell Lung Cancer. Journal of Environmental Pathology, Toxicology and Oncology, 2004, 23, 16. | 1.2 | 18 |
| 344 | Targeted molecules in small cell lung cancer. Seminars in Oncology, 2004, 31, 106-111. | 2.8 | 46 |
| 345 | Targeting c-Kit mutations: basic science to novel therapies. Leukemia Research, 2004, 28, 11-20. | 0.7 | 85 |
| 346 | The role of ephrins and Eph receptors in cancer. Cytokine and Growth Factor Reviews, 2004, 15, 419-433. | 7.3 | 324 |
| 347 | Integrin dependent protein tyrosine phosphorylation is a key regulatory event in collagen IV mediated adhesion and proliferation of human lung tumor cell line, Calu-1. Annals of Thoracic Surgery, 2004, 78, 450-457. | 2.6 | 18 |
| 348 | Title is missing!. Cancer and Metastasis Reviews, 2003, 22, 309-325. | 6.8 | 473 |
| 349 | p53 and Bcl-2 in Small-Cell Lung Cancer. Clinical Lung Cancer, 2003, 4, 303. | 2.1 | 0 |
| 350 | Benefit of Active Treatment in Non–Small-Cell Lung Cancer in Elderly Patients and Patients with Poor Performance Status. Clinical Lung Cancer, 2003, 5, 86-89. | 2.1 | 4 |
| 351 | Molecular and cellular biology of small cell lung cancer. Seminars in Oncology, 2003, 30, 57-71. | 2.8 | 67 |
| 352 | Small cell lung cancer: from molecular biology to novel therapeutics. Journal of Experimental Therapeutics and Oncology, 2003, 3, 305-318. | 1.1 | 14 |
| 353 | P-324 c-Met/HGF signaling through P13K with effects on cytoskeletal functions in small cell lung cancer. Lung Cancer, 2003, 41, S173-S174. | 1.8 | 1 |
| 354 | Use of Temozolomide with Other Cytotoxic Chemotherapy in the Treatment of Patients with Recurrent Brain Metastases from Lung Cancer. Oncologist, 2003, 8, 69-75. | 2.5 | 51 |
| 355 | Vaccination With Irradiated Autologous Tumor Cells Engineered to Secrete Granulocyte-Macrophage Colony-Stimulating Factor Augments Antitumor Immunity in Some Patients With Metastatic Non–Small-Cell Lung Carcinoma. Journal of Clinical Oncology, 2003, 21, 624-630. | 12.4 | 282 |
| 356 | Small-Cell Cancers, and an Unusual Reaction to Chemotherapy. Journal of Clinical Oncology, 2003, 21, 2437-2438. | 12.4 | 12 |
| 357 | Unusual Problems in Breast Cancer and a Rare Lung Cancer Case. Journal of Clinical Oncology, 2003, 21, 2220-2222. | 12.4 | 5 |
| 358 | 2-Methoxyestradiol alters cell motility, migration, and adhesion. Blood, 2003, 102, 289-296. | 3.6 | 43 |
| 359 | Mechanisms of Metastasis as Related to Receptor Tyrosine Kinases in Small-Cell Lung Cancer. Journal of Environmental Pathology, Toxicology and Oncology, 2003, 22, 147-166. | 1.2 | 21 |
| 360 | Vascular Endothelial Growth Factor-induced Migration of Multiple Myeloma Cells Is Associated with β1 Integrin- and Phosphatidylinositol 3-Kinase-dependent PKCα Activation. Journal of Biological Chemistry, 2002, 277, 7875-7881. | 1.3 | 166 |

| # | Article | IF | Citations |
|---|---|---|---|
| 361 | ATP6S1 elicits potent humoral responses associated with immune-mediated tumor destruction. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 6919-6924. | 5.2 | 46 |
| 362 | CD2 molecules redistribute to the uropod during T cell scanning: Implications for cellular activation and immune surveillance. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 7582-7587. | 5.2 | 49 |
| 363 | A Fragment of Paxillin Binds the α4Integrin Cytoplasmic Domain (Tail) and Selectively Inhibits α4-Mediated Cell Migration. Journal of Biological Chemistry, 2002, 277, 20887-20894. | 1.3 | 52 |
| 364 | Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. Cytokine and Growth Factor Reviews, 2002, 13, 41-59. | 7.3 | 380 |
| 365 | Gemcitabine-induced radiation recall. International Journal of Radiation Oncology Biology Physics, 2002, 53, 394-400. | 1.3 | 132 |
| 366 | Differential expression and signaling of CBL and CBL-B in BCR/ABL transformed cells. Oncogene, 2002, 21, 1423-1433. | 5.2 | 26 |
| 367 | Gemcitabine and vinorelbine in patients with advanced lung cancer: preclinical studies and report of a phase I trial. Cancer Chemotherapy and Pharmacology, 2001, 48, 151-159. | 1.3 | 28 |
| 368 | SHIP1, an SH2 Domain Containing Polyinositol-5-phosphatase, Regulates Migration through Two Critical Tyrosine Residues and Forms a Novel Signaling Complex with DOK1 and CRKL. Journal of Biological Chemistry, 2001, 276, 2451-2458. | 1.3 | 51 |
| 369 | Chemokine Receptors CXCR-1/2 Activate Mitogen-activated Protein Kinase via the Epidermal Growth Factor Receptor in Ovarian Cancer Cells. Journal of Biological Chemistry, 2000, 275, 6868-6875. | 1.3 | 191 |
| 370 | Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571. Oncogene, 2000, 19, 3521-3528. | 5.2 | 229 |
| 371 | Case 1: Small Bowel Obstruction Due to Metastatic Lung Cancer. Journal of Clinical Oncology, 2000, 18, 227-227. | 12.4 | 15 |
| 372 | The Noncatalytic Domain of Protein-tyrosine Phosphatase-PEST Targets Paxillin for Dephosphorylation in Vivo. Journal of Biological Chemistry, 2000, 275, 1405-1413. | 1.3 | 63 |
| 373 | The BCR/ABL Tyrosine Kinase Induces Production of Reactive Oxygen Species in Hematopoietic Cells. Journal of Biological Chemistry, 2000, 275, 24273-24278. | 1.3 | 288 |
| 374 | Role of the Cytoskeletal Protein Paxillin in Oncogenesis. Critical Reviews in Oncogenesis, 2000, 11, 14. | 0.6 | 46 |
| 375 | Molecular Cloning and Characterization of Human Trabeculin-α, a Giant Protein Defining a New Family of Actin-binding Proteins. Journal of Biological Chemistry, 1999, 274, 33522-33530. | 1.3 | 40 |
| 376 | The Role of Focal Adhesion Kinase Binding in the Regulation of Tyrosine Phosphorylation of Paxillin. Journal of Biological Chemistry, 1999, 274, 36684-36692. | 1.3 | 133 |
| 377 | Expression of the focal adhesion protein paxillin in lung cancer and its relation to cell motility. Oncogene, 1999, 18, 67-77. | 5.2 | 83 |
| 378 | Involvement of the adapter protein CRKL in integrin-mediated adhesion. Oncogene, 1999, 18, 3343-3353. | 5.2 | 29 |

| # | Article | IF | Citations |
|---|---|---|---|
| 379 | Role of the adapter protein CRKL in signal transduction of normal hematopoietic and BCR/ABL-transformed cells. Leukemia, 1998, 12, 637-644. | 3.7 | 104 |
| 380 | Cancer-associated retinopathy in a patient with non-small-cell lung carcinoma. Lung Cancer, 1998, 22, 149-152. | 1.8 | 33 |
| 381 | A cdc15-like adaptor protein (CD2BP1) interacts with the CD2 cytoplasmic domain and regulates CD2-triggered adhesion. EMBO Journal, 1998, 17, 7320-7336. | 5.1 | 95 |
| 382 | Steel Factor Induces Tyrosine Phosphorylation of CRKL and Binding of CRKL to a Complex Containing c-Kit, Phosphatidylinositol 3-Kinase, and p120CBL. Journal of Biological Chemistry, 1997, 272, 10248-10253. | 1.3 | 96 |
| 383 | Involvement of p130Cas and p105HEF1, a Novel Cas-like Docking Protein, in a Cytoskeleton-dependent Signaling Pathway Initiated by Ligation of Integrin or Antigen Receptor on Human B Cells. Journal of Biological Chemistry, 1997, 272, 4230-4236. | 1.3 | 112 |
| 384 | The Bovine Papillomavirus E6 Protein Binds to the LD Motif Repeats of Paxillin and Blocks Its Interaction with Vinculin and the Focal Adhesion Kinase. Journal of Biological Chemistry, 1997, 272, 33373-33376. | 1.3 | 82 |
| 385 | Differential Signaling after β1 Integrin Ligation Is Mediated Through Binding of CRKL to p120 and p110. Journal of Biological Chemistry, 1997, 272, 14320-14326. | 1.3 | 90 |
| 386 | Activation of hematopoietic growth factor signal transduction pathways by the human oncogene BCR/ABL. Cytokine and Growth Factor Reviews, 1997, 8, 63-79. | 7.3 | 101 |
| 387 | Association of the Cas-like Molecule HEF1 with CrkL Following Integrin and Antigen Receptor Signaling in Human B-Cells: Potential Relevance to Neoplastic Lymphohematopoietic Cells. Leukemia and Lymphoma, 1997, 28, 65-72. | 1.0 | 40 |
| 388 | The BCR/ABL oncogene alters interaction of the adapter proteins CRKL and CRK with cellular proteins. Leukemia, 1997, 11, 376-385. | 3.7 | 45 |
| 389 | The phosphatidylinositol polyphosphate 5-phosphatase SHIP and the protein tyrosine phosphatase SHP-2 form a complex in hematopoietic cells which can be regulated by BCR/ABL and growth factors. Oncogene, 1997, 15, 2379-2384. | 5.2 | 73 |
| 390 | Thrombopoietin induces activation of the phosphatidylinositol-3' kinase pathway and formation of a complex containing p85PI3K and the protooncoprotein p120CBL. Journal of Cellular Physiology, 1997, 171, 28-33. | 2.5 | 35 |
| 391 | BCR/ABL induces multiple abnormalities of cytoskeletal function.. Journal of Clinical Investigation, 1997, 100, 46-57. | 6.6 | 157 |
| 392 | Role of Focal Adhesion Proteins in Signal Transduction and Oncogenesis. Critical Reviews in Oncogenesis, 1997, 8, 343-358. | 0.6 | 62 |
| 393 | The Related Adhesion Focal Tyrosine Kinase Forms a Complex with Paxillin in Hematopoietic Cells. Journal of Biological Chemistry, 1996, 271, 31222-31226. | 1.3 | 131 |
| 394 | p130CAS Forms a Signaling Complex with the Adapter Protein CRKL in Hematopoietic Cells Transformed by the BCR/ABL Oncogene. Journal of Biological Chemistry, 1996, 271, 25198-25203. | 1.3 | 111 |
| 395 | CRKL Links p210BCR/ABL with Paxillin in Chronic Myelogenous Leukemia Cells. Journal of Biological Chemistry, 1995, 270, 29145-29150. | 1.3 | 115 |
| 396 | Molecular Cloning Of Human Paxillin, a Focal Adhesion Protein Phosphorylated by P210BCR/ABL. Journal of Biological Chemistry, 1995, 270, 5039-5047. | 1.3 | 252 |

| # | Article | IF | Citations |
|---|---|---|---|
| 397 | Changes in Tc-99m radionuclide bone scan images and peripheralizatioin of marrow hematopoetic activity associated with the administration of granulocyte colony stimulating factor as an adjunct to dose-intensified chemotherapy for breast cancer. Cancer, 1994, 74, 1887-1890. | 2.7 | 10 |
| 398 | Shc phosphorylation in myeloid cells is regulated by granulocyte macrophage colony-stimulating factor, interleukin-3, and steel factor and is constitutively increased by p210BCR/ABL.. Journal of Biological Chemistry, 1994, 269, 5016-5021. | 1.3 | 142 |
| 399 | Altered membrane fluidity in rat hepatocytes during endotoxic shock. Molecular and Cellular Biochemistry, 1993, 121, 143-148. | 2.4 | 12 |
| 400 | Degradation and regurgitation of extracellular proteins by cultured mouse peritoneal macrophages and baby hamster kidney fibroblasts. Kinetic evidence that the transfer of proteins to lysosomes is not irreversible.. Journal of Biological Chemistry, 1987, 262, 9469-9476. | 1.3 | 41 |
| 401 | Exploring the Next Frontier in Non–Small-Cell Lung Cancer With High MET and Mutated Epidermal Growth Factor Receptor. Journal of Clinical Oncology, 0, 41, 1129-1131. | 12.4 | 0 |
| 402 | Title is missing!. , 0, . | | 1 |
| 403 | Small Cell Transformation of EGFR-Mutant NSCLC Treated with Tyrosine Kinase Inhibition. Current Oncology, 0, 32, 554. | 2.0 | 4 |
| 404 | Current Clinical Paradigm and Therapeutic Advancements in Thymic Malignancies: A Narrative Review. Cancers, 0, 17, 3622. | 2.7 | 3 |
| 405 | Hyperthermia-induced apoptosis: The role of magnetic nanoparticles in targeted delivery for breast cancer treatment. Biochimica Et Biophysica Acta: Reviews on Cancer, 0, 1880, 189490. | 5.8 | 8 |
| 406 | RLIP depletion suppresses ovarian cancer growth and metastasis. Journal of Ovarian Research, 0, 19, . | 2.8 | 0 |
| 407 | Emerging trends and treatment strategies in ovarian cancer: A comprehensive review. Critical Reviews in Oncology/Hematology, 0, 220, 105177. | 3.5 | 4 |
| 408 | Epitranscriptomic signatures of malignancy: how RNA modifications shape breast and ovarian tumor progression. Biochemical Pharmacology, 0, 248, 117872. | 3.7 | 0 |
| 409 | mRNA-based cancer vaccines: A new frontier in personalized immunotherapy. Biochimica Et Biophysica Acta: Reviews on Cancer, 0, 1881, 189577. | 5.8 | 4 |
| 410 | Abstract 7127: RalBP1 inhibition: A novel therapy for prostate cancer. Cancer Research, 0, 86, 7127-7127. | 2.6 | 0 |
| 411 | Abstract 1807: RLIP depletion suppresses ovarian cancer growth and metastasis.. Cancer Research, 0, 86, 1807-1807. | 2.6 | 0 |
| 412 | Abstract 5997: Network based mapping reveals mechanistic drivers and targetable hubs contributing to Sotorasib resistance in KRAS G12C lung cancer. Cancer Research, 0, 86, 5997-5997. | 2.6 | 0 |
| 413 | STK11 as an Emerging Biomarker in Non-Small Cell Lung Cancer. Current Oncology, 0, 33, 241. | 2.0 | 0 |
| 414 | Chemoresistance in gynecologic cancers: mechanistic insights and emerging platforms to overcome drug failure. Journal of Ovarian Research, 0, 19, . | 2.8 | 5 |

| # | Article | IF | Citations |
|---|---|---|---|
| 415 | Inflammation-driven transcriptional reprogramming in prostate cancer: Convergence of NFκB, JAK/STAT3, and epigenetic remodeling in castration-resistant disease. Cancer Letters, 0, 655, 218647. | 6.5 | 0 |
| 416 | AI-Driven Design of High Affinity Biomolecule–Drug Conjugates for Gynecological Cancer Therapy: An Up-to-Date Narrative Review. Cancers, 0, 18, 1856. | 2.7 | 0 |
| 417 | PP01.31: Genomic Predictors of Response to Platinum-Based Chemotherapy and Immunotherapy in Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 0, 21, 104029. | 1.5 | 0 |